Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 8, Issue 1, Pages 57-64Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2007.12.002
Keywords
-
Categories
Funding
- NIMH NIH HHS [R01 MH060244-07, MH60244, R01 MH060244] Funding Source: Medline
- NINDS NIH HHS [R01 NS046742, R01 NS046742-04, NS46742] Funding Source: Medline
Ask authors/readers for more resources
Epigenetic chromatin remodeling and modifications of DNA represent central mechanisms for regulation of gene expression during brain development and in memory formation. Emerging evidence implicates epigenetic modifications in disorders of synaptic plasticity and cognition. This review focuses on recent findings that HDAC inhibitors can ameliorate deficits in synaptic plasticity, cognition, and stress-related behaviors in a wide range of neurologic and psychiatric disorders including Huntington's disease, Parkinson's disease, anxiety and mood disorders, Rubinstein-Taybi syndrome, and Rett syndrome. These agents may prove useful in the clinic for the treatment of the cognitive impairments that are central elements of many neurodevelopmental, neurological, and psychiatric disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available